NO20012114L - Chaperonekompleks med <beta>-amyloid og anvendelse av komplekset - Google Patents

Chaperonekompleks med <beta>-amyloid og anvendelse av komplekset

Info

Publication number
NO20012114L
NO20012114L NO20012114A NO20012114A NO20012114L NO 20012114 L NO20012114 L NO 20012114L NO 20012114 A NO20012114 A NO 20012114A NO 20012114 A NO20012114 A NO 20012114A NO 20012114 L NO20012114 L NO 20012114L
Authority
NO
Norway
Prior art keywords
disease
complex
level
alzheimer
amyloid
Prior art date
Application number
NO20012114A
Other languages
English (en)
Other versions
NO331974B1 (no
NO20012114D0 (no
Inventor
Jordan Holtzman
Original Assignee
Jordan Holtzman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordan Holtzman filed Critical Jordan Holtzman
Publication of NO20012114D0 publication Critical patent/NO20012114D0/no
Publication of NO20012114L publication Critical patent/NO20012114L/no
Publication of NO331974B1 publication Critical patent/NO331974B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20012114A 1998-10-30 2001-04-27 Fremgangsmate for a detektere i en biologisk prove et kompleks av chaperon Q2 og beta-amyloid, antistoff som gjenkjenner komplekset og anvendelse av chaperon Q2 for fremstilling av et preparat for behandling av Alzheimers sykdom. NO331974B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639898P 1998-10-30 1998-10-30
US12356499P 1999-03-10 1999-03-10
PCT/US1999/025593 WO2000026251A2 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Publications (3)

Publication Number Publication Date
NO20012114D0 NO20012114D0 (no) 2001-04-27
NO20012114L true NO20012114L (no) 2001-06-14
NO331974B1 NO331974B1 (no) 2012-05-14

Family

ID=26803625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012114A NO331974B1 (no) 1998-10-30 2001-04-27 Fremgangsmate for a detektere i en biologisk prove et kompleks av chaperon Q2 og beta-amyloid, antistoff som gjenkjenner komplekset og anvendelse av chaperon Q2 for fremstilling av et preparat for behandling av Alzheimers sykdom.

Country Status (12)

Country Link
US (3) US6972318B1 (no)
EP (1) EP1125135B1 (no)
JP (1) JP4571310B2 (no)
AT (1) ATE284538T1 (no)
AU (1) AU764713B2 (no)
CA (1) CA2348545C (no)
DE (1) DE69922535T2 (no)
IL (2) IL142852A0 (no)
MX (1) MXPA01004317A (no)
NO (1) NO331974B1 (no)
NZ (1) NZ511589A (no)
WO (1) WO2000026251A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153058A0 (en) * 2000-05-24 2003-06-24 Jordan Loyal Holtzman Agents and methods for increasing brain chaperonin levels
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
ES2294196T3 (es) * 2002-12-20 2008-04-01 F. Hoffmann-La Roche Ag Metodos para elaborar y utilizar complejos solubles de proteinas diana y chaperonas peptil prolil isomerasas.
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP4981305B2 (ja) * 2005-11-11 2012-07-18 公益財団法人大阪バイオサイエンス研究所 アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
TW201214809A (en) * 2010-01-29 2012-04-01 Nitto Denko Corp Light-emitting diode device
US9522170B2 (en) 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2014012108A1 (en) * 2012-07-13 2014-01-16 Holtzman Jordan L Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
WO2018067854A1 (en) * 2016-10-06 2018-04-12 Ramp Research, Llc Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5707821A (en) 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
IL136306A (en) 1997-12-10 2005-09-25 Nps Pharma Inc Bis (fluorophenyl) alkylamides and related compounds, pharmaceutical compositions comprising them and their use in treating neurological disease or disorder

Also Published As

Publication number Publication date
NO331974B1 (no) 2012-05-14
US8211658B2 (en) 2012-07-03
JP4571310B2 (ja) 2010-10-27
WO2000026251A9 (en) 2001-01-04
CA2348545A1 (en) 2000-05-11
AU764713B2 (en) 2003-08-28
NZ511589A (en) 2005-02-25
EP1125135B1 (en) 2004-12-08
US20060024759A1 (en) 2006-02-02
AU1810500A (en) 2000-05-22
WO2000026251A2 (en) 2000-05-11
DE69922535T2 (de) 2005-05-12
NO20012114D0 (no) 2001-04-27
IL142852A0 (en) 2002-03-10
WO2000026251A3 (en) 2000-08-10
CA2348545C (en) 2012-08-21
EP1125135A2 (en) 2001-08-22
MXPA01004317A (es) 2003-06-06
ATE284538T1 (de) 2004-12-15
US6972318B1 (en) 2005-12-06
JP2002528555A (ja) 2002-09-03
IL142852A (en) 2010-05-31
US7927824B2 (en) 2011-04-19
US20110256569A1 (en) 2011-10-20
DE69922535D1 (de) 2005-01-13

Similar Documents

Publication Publication Date Title
Oka et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin‐reactive α‐fetoprotein 1
Schwabl et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension
Sjogren et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Gervil et al. The relative role of genetic and environmental factors in migraine without aura
NO20012114L (no) Chaperonekompleks med &lt;beta&gt;-amyloid og anvendelse av komplekset
Margolis et al. Huntington's disease–like 2 (HDL2) in North America and Japan
Olynyk et al. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging
GB0512401D0 (en) Method
Gümüşay et al. Diagnostic potential of serum direct markers and non‐invasive fibrosis models in patients with chronic hepatitis B
El-Mezayen et al. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study
ATE447713T1 (de) S100-proteine und -autoantikörper als serummarker für krebs
Gürleyik et al. Serum interleukin‐6 measurement in the diagnosis of acute appendicitis
Giannitrapani et al. Nontumorous portal vein thrombosis in liver cirrhosis: possible role of β-blockers
Świderska et al. Serum cytokeratin 18 M30 levels in chronic hepatitis B reflect both phase and histological activities of disease
Cheong et al. A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis
Alboraie et al. Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study
KR102591417B1 (ko) 대변 모니터링 및 건강 지도 장치
Kelly et al. The relationship between acute ischaemic stroke and plasma D-dimer levels in patients developing neither venous thromboembolism nor major intercurrent illness
DK0514490T3 (da) Allelisk forbindelse af human dopamin (D2) receptorgenet i kompulsionsforstyrrelser, såsom alkoholisme
Maskell et al. A normal serum CRP measurement does not exclude deep vein thrombosis
Malcolm et al. Carbohydrate-deficient transferrin and alcohol use in medical examiner cases
Hota et al. Role of eosinophil count and neutrophil: lymphocyte count ratio as prognostic markers in patients with sepsis
JP2006300689A (ja) 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法
FI990380A0 (fi) Diagnostinen ja seulontamenetelmä
DE68928106D1 (de) Nachweis, quantifizierung und klassifizierung von ras-proteinen in körperflüssigkeiten und geweben

Legal Events

Date Code Title Description
ERR Erratum

Free format text: I PATENTTIDENDE NR. 22/07 BLE PATENTSOKNAD NR. 20012114 FEILAKTIG KUNNGJORT ENDELIG HENLAGT. SOKNADEN ER FORTSATT UNDER BEHANDLING

Free format text: I PATENTTIDENDE NR. 22/07 BLE PATENTSOKNAD NR. 20012114 FEILAKTIG KUNNGJORT ENDELIG HENLAGT. SOKNADEN ER FORTSATT UNDER BEHANDLING.

MM1K Lapsed by not paying the annual fees